NCT02764333View on ClinicalTrials.gov

TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

May 6, 2016

Primary Completion Date

January 20, 2021

Study Completion Date

January 20, 2021

Conditions
Ovarian Cancer
Interventions
BIOLOGICAL

TPIV200

BIOLOGICAL

Durvalumab

Trial Locations (5)

10604

Memorial Sloan Kettering Westchester, Harrison

11570

Memorial Sloan Kettering Cancer Center at Rockville, Rockville Centre

11725

Memorial Sloan Kettering Cancer Center @ Commack, Commack

07920

Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

Sponsors
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Marker Therapeutics, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER